The sixth European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) opened today at the Edinburgh International Conference Centre (EICC).
Findings in this study confirmed the herd immunity effect of immunizing young children, since invasive meningococcal disease was not only reduced among vaccinees, but in all age groups.
The authors assess the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011 (this period included a large outbreak in 2010).
Carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase-producing Enterobacteriaceae (CPE) are highly resistant to antibiotics, leaving only a few options for treatment of infected patients, and thus represent a serious threat to public health.
The annual meeting of the healthcare-associated infections surveillance network (HAI-Net) and of the HAI-Net coordination group took place in Stockholm on 19-21 June 2012.
WHO “SAVE LIVES: Clean Your Hands” is an annual campaign that makes part of major global effort to support healthcare workers to improve hand hygiene practices in healthcare settings, and thus support the prevention of often life-threatening healthcare-associated infections.
This study, strong of an almost complete follow-up of all children born in Denmark from 2003 to 2008, provides evidence that the DTaP-IPV-HiB vaccine is not associated to an overall increased risk of febrile seizures and epilepsy.
This workshop enabled all to agree on the relevance of EPIS VPD to be used as a platform for the reporting and monitoring of measles outbreak in the EU, agree on the type of information to be reported, the nature of outbreaks to be notified and the further usage by ECDC (e.g. European Monthly Measles Monitoring1) and other Member States of data that will be shared through EPIS VPD by countries.
A meeting and a workshop on the ECDC point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use in acute care hospitals took take place in London on 5-6 March 2012.
4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.